eureKARE spawns SPAC 'to compete with the leading international CDMOs'

12 May 2022

Investment company eureKARE, which is focused on financing and building biotech companies in the disruptive fields of synthetic biology and the microbiome, has announced the emergence of eureKING (Euronext: SINGS).

This new special purpose acquisition company (SPAC) has been launched with a 150 million euros ($158 million) listing and the aim of acquiring European companies in the field of biomanufacturing. The ambition is to create a leading bio-CDMO in Europe capable of meeting the growing outsourcing needs of the industry.

"The first European healthcare SPAC dedicated to biomanufacturing"As founders of eureKING, eureKARE and its chief executive Rodolphe Besserve have said that they bring biopharma expertise, combining new industry monitoring and analysis with a strong track record of quick, agile and transparent investment processes.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK